JP2005501847A - イソキサゾロピリジノン類 - Google Patents

イソキサゾロピリジノン類 Download PDF

Info

Publication number
JP2005501847A
JP2005501847A JP2003520739A JP2003520739A JP2005501847A JP 2005501847 A JP2005501847 A JP 2005501847A JP 2003520739 A JP2003520739 A JP 2003520739A JP 2003520739 A JP2003520739 A JP 2003520739A JP 2005501847 A JP2005501847 A JP 2005501847A
Authority
JP
Japan
Prior art keywords
alkyl
alkylamino
alkoxy
phenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003520739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005501847A5 (enExample
Inventor
ザムエル・ヒンターマン
バスティアン・ヘンゲラー
ウルリケ・フォン・クロジッヒク
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2005501847A publication Critical patent/JP2005501847A/ja
Publication of JP2005501847A5 publication Critical patent/JP2005501847A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2003520739A 2001-08-15 2002-08-14 イソキサゾロピリジノン類 Withdrawn JP2005501847A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0119911.6A GB0119911D0 (en) 2001-08-15 2001-08-15 Organic Compounds
PCT/EP2002/009134 WO2003015780A2 (en) 2001-08-15 2002-08-14 Isoxazolopyridinones and use thereof in the treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
JP2005501847A true JP2005501847A (ja) 2005-01-20
JP2005501847A5 JP2005501847A5 (enExample) 2005-10-06

Family

ID=9920454

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003520739A Withdrawn JP2005501847A (ja) 2001-08-15 2002-08-14 イソキサゾロピリジノン類

Country Status (24)

Country Link
US (1) US7087756B2 (enExample)
EP (1) EP1418912B1 (enExample)
JP (1) JP2005501847A (enExample)
KR (1) KR20040029429A (enExample)
CN (1) CN100384418C (enExample)
AR (1) AR036351A1 (enExample)
AT (1) ATE355059T1 (enExample)
BR (1) BR0211903A (enExample)
CA (1) CA2454762A1 (enExample)
CO (1) CO5560566A2 (enExample)
DE (1) DE60218484T2 (enExample)
EC (1) ECSP044971A (enExample)
ES (1) ES2282467T3 (enExample)
GB (1) GB0119911D0 (enExample)
HU (1) HUP0401325A3 (enExample)
IL (1) IL160018A0 (enExample)
MX (1) MXPA04001419A (enExample)
NO (1) NO20040659D0 (enExample)
PE (1) PE20030356A1 (enExample)
PL (1) PL366848A1 (enExample)
PT (1) PT1418912E (enExample)
RU (1) RU2004107847A (enExample)
WO (1) WO2003015780A2 (enExample)
ZA (1) ZA200400525B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504309A (ja) * 2006-09-22 2010-02-12 サノフイ−アベンテイス ２−アリール−６−フェニルイミダゾ［１，２−α］ピリジン誘導体、これらの調製およびこれらの治療的使用
JP2011527326A (ja) * 2008-07-10 2011-10-27 ラボラトワール フルニエ エス・アー パーキンソン病を治療するためのｎｕｒｒ−１活性化剤としてのインドール誘導体の使用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2451057A1 (en) * 2001-06-14 2002-12-27 Banyu Pharmaceutical Co., Ltd. Novel isoxazolopyridone derivatives and use thereof
US7820705B2 (en) * 2004-05-14 2010-10-26 Irm Llc Compounds and compositions as PPAR modulators
CA2642672A1 (en) * 2006-02-16 2007-08-30 The Mclean Hospital Corporation Methods and compositions for the treatment of parkinson's disease
AU2007275301A1 (en) 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
EP2376079B1 (en) * 2009-01-13 2016-08-10 Van Andel Research Institute Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids
FR2950053B1 (fr) 2009-09-11 2014-08-01 Fournier Lab Sa Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
FR2955110A1 (fr) 2010-01-08 2011-07-15 Fournier Lab Sa Nouveaux derives de type pyrrolopyridine benzoique
DE102011085038A1 (de) 2011-10-21 2013-04-25 Tesa Se Verfahren zur Kapselung einer elektronischen Anordnung
WO2015048316A1 (en) 2013-09-25 2015-04-02 Van Andel Research Institute Highly potent glucocorticoids
KR20170033630A (ko) 2015-09-17 2017-03-27 (주)다올 도로용 경계블럭
JP7146750B2 (ja) 2016-10-14 2022-10-04 ヴァン アンデル リサーチ インスティテュート 非常に強力な糖質コルチコイドの構造およびデザインのための機構

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7602542L (sv) 1975-03-14 1976-09-15 Sandoz Ag 3-(alfa-iminobensyl)-4-hydroxi-2(lh)-pyridoner
US4064251A (en) * 1976-06-25 1977-12-20 Sandoz, Inc. Substituted hydroxy pyridones
US4049813A (en) * 1976-07-15 1977-09-20 Sandoz, Inc. Substituted isoxazolo pyridinones
DE2801190A1 (de) * 1977-01-19 1978-07-20 Sandoz Ag 3-(alpha-iminobenzyl)-4-hydroxy-2(1h)- pyridon-derivat
US4238616A (en) * 1977-01-19 1980-12-09 Sandoz, Inc. 3-(Substituted)phenyl-5-(β-hydroxyphenethyl)-N-(alkyl)-isoxazole-4-carboxamides
US4113727A (en) * 1977-04-26 1978-09-12 Sandoz, Inc. Process for the preparation of substituted isoxazolo[4,5-c]pyridin-4-(5H)-ones
CA2451057A1 (en) * 2001-06-14 2002-12-27 Banyu Pharmaceutical Co., Ltd. Novel isoxazolopyridone derivatives and use thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504309A (ja) * 2006-09-22 2010-02-12 サノフイ−アベンテイス ２−アリール−６−フェニルイミダゾ［１，２−α］ピリジン誘導体、これらの調製およびこれらの治療的使用
JP2011527326A (ja) * 2008-07-10 2011-10-27 ラボラトワール フルニエ エス・アー パーキンソン病を治療するためのｎｕｒｒ−１活性化剤としてのインドール誘導体の使用

Also Published As

Publication number Publication date
CO5560566A2 (es) 2005-09-30
DE60218484D1 (de) 2007-04-12
WO2003015780A3 (en) 2003-11-13
HUP0401325A2 (hu) 2004-10-28
WO2003015780A2 (en) 2003-02-27
MXPA04001419A (es) 2004-05-27
PL366848A1 (en) 2005-02-07
ZA200400525B (en) 2005-04-01
CN1635889A (zh) 2005-07-06
ATE355059T1 (de) 2006-03-15
DE60218484T2 (de) 2007-11-15
ES2282467T3 (es) 2007-10-16
US7087756B2 (en) 2006-08-08
ECSP044971A (es) 2004-03-23
GB0119911D0 (en) 2001-10-10
NO20040659L (no) 2004-02-13
RU2004107847A (ru) 2005-05-10
CN100384418C (zh) 2008-04-30
BR0211903A (pt) 2004-09-21
CA2454762A1 (en) 2003-02-27
AR036351A1 (es) 2004-09-01
IL160018A0 (en) 2004-06-20
US20040248893A1 (en) 2004-12-09
PE20030356A1 (es) 2003-05-14
PT1418912E (pt) 2007-05-31
EP1418912A2 (en) 2004-05-19
EP1418912B1 (en) 2007-02-28
NO20040659D0 (no) 2004-02-13
HUP0401325A3 (en) 2005-09-28
KR20040029429A (ko) 2004-04-06
WO2003015780A8 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
JP6638036B2 (ja) 有機化合物
JP6051210B2 (ja) 有機化合物
JP5536135B2 (ja) 有機化合物
TW201206944A (en) Morpholine compounds
JP2005501847A (ja) イソキサゾロピリジノン類
JP7041141B2 (ja) 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤
JP2012505230A (ja) ピロロンメラニン凝集ホルモン受容体１拮抗薬
KR20130038242A (ko) 벤즈아제핀 화합물
AU2002336977A1 (en) Isoxazolopyridinones and use thereof in the treatment of Parkinson's disease
CN114656480B (zh) 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114671876A (zh) 新型茶碱类化合物、异构体或盐及其制备方法和用途

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071002

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20071218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080416

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20080422

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20080516

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110218